Treating Together

Targeted Oncology

0.0 (0)
HEALTH & FITNESS
UPDATED MONTHLY

Targeted Oncology brings you Treating Together, a podcast series designed to bring oncologists into meaningful, peer-driven conversations by focusing on real-world challenges, clinical relevance of emerging data, and bridging the gap between research and frontline oncology care across different cancer types.

2D AGO

Navigating the Future of CLL Care

In this episode of Treating Together, host Marc Braunstein, MD, an associate professor of medicine at the Perlmutter Cancer Center, NYU Grossman School of Medicine, is joined by John Burke, MD, from Rocky Mountain Cancer Centers. Both specialists bring their extensive experience in lymphoma and multiple myeloma to a deep-dive discussion on the rapidly evolving treatment landscape of chronic lymphocytic leukemia (CLL). Key Discussion PointsThe episode focuses on the refinement of CLL therapy, moving away from traditional chemoimmunotherapy toward targeted approaches. Highlights include: Continuous vs. fixed-duration therapy: A debate on whether patients benefit more from indefinite BTK inhibitor use or time-limited regimens. The role of MRD: Exploring how minimal residual disease (MRD) driven duration is becoming a sophisticated option for tailoring treatment. Clinical trial updates: Analysis of recent data regarding frontline treatment outcomes and infectious risks. Relapsed/refractory strategies: Insights into the recent FDA approval of pirtobrutinib (Jaypirca) for second-line therapy and beyond. Looking Toward the FutureAs the experts look ahead into 2026, they discuss the promising emergence of BTK degraders, which have shown high response rates in heavily pretreated patients and are moving toward potential market availability in the coming years.

17 min
JAN 21

Supporting Community Oncologists in a GU Research Era with Dr. Park, Dr. Garmezy, and Dr. Bupathi

This episode of Treating Together, hosted by Chandler Park, MD, featuring guests Benjamin Garmezy, MD, and Manoj Bupathi, MD, centers on the intersection of clinical research and community oncology, specifically within the field of genitourinary (GU) oncology. Core Themes and Discussion Points The Community Oncology Gap: Park highlights a critical statistic: 80% to 85% of patients with cancer are treated in community settings rather than academic centers. The podcast aims to support these community clinicians by translating complex data into practical applications. Rapidly Evolving Data: The group discusses the immense challenge of staying current with novel biomarkers, immunotherapy, targeted therapies, and AI in pathology. The Burden on Generalists: Garmezy notes that while specialists find it hard to keep up, the "real heroes" are the general community oncologists who see a wide variety of conditions and may only see a handful of GU-specific cases per year. Bridging the Research Divide: A primary goal is to narrow the gap between clinical trial findings and real-world clinical practice, ensuring that patients in the community benefit from the latest research. Find a full transcript of the podcast at https://www.targetedonc.com/view/supporting-community-oncologists-in-a-gu-research-era

27 min
12/15/2025 · BONUS

Gut Health & Myeloma: How Bacteria May Predict Transplant Success With Pooja Phull, MD

Treating Together

7 min
10/31/2025

Experts Delve Into Organ Preservation for Genitourinary Cancers

Benjamin Garmezy, MD, and Alexander Kenigsberg, MD, discuss strategies for preserving organs in GU cancers in the Treating Together podcast.

26 min
09/29/2025

Navigating Modern Lung Cancer Treatment and Clinical Trial Access

Edward S. Kim, MD, MBA, and Neel Shah, MD, discuss advancing lung cancer care and tackling real-world access barriers for community physicians.

23 min
07/31/2025

Advancing Prostate Cancer Treatment With Shared Decision-Making

In our first episode of Treating Together, Benjamin Garmezy, MD, and Ralph J. Miller Jr, MD, discuss multidisciplinary prostate cancer care.

25 min
04/15/2025

Predicting Palbociclib Outcomes in Breast Cancer Using Deep Learning

In this episode of Emerging Experts, Xiaojie Zhang, MD, a hematology/oncology fellow, and Akshat Singhal, PhD, a postdoctoral scholar, both at UC San Diego, shed light on innovative research leveraging deep learning to predict how patients with ER-positive/HER2-negative (ER+/HER2-) breast cancer will respond to palbociclib (Ibrance), a common first-line treatment for this patient population. Their work, fueled by the desire to improve precision oncology, demonstrates the significant potential of artificial intelligence (AI) in guiding cancer care.

37 min
03/13/2025

BMT CTN 1902 in Myeloma: Key Findings With Garfall

In this episode of Targeted Talks, Alfred L. Garfall, MD, discusses the phase 2 BMT CTN 1902 trial (NCT05032820) of idecabtagene vicleucel (ide-cel; Abecma), a study focused on patients with multiple myeloma who had a suboptimal response to first-line therapy, including autologous hematopoietic cell transplant and lenalidomide (Revlimid) maintenance.

15 min

Targeted Oncology brings you Treating Together, a podcast series designed to bring oncologists into meaningful, peer-driven conversations by focusing on real-world challenges, clinical relevance of emerging data, and bridging the gap between research and frontline oncology care across different cancer types.

Creator

Targeted Oncology
Years Active

2020 - 2026
Episodes

77
Rating

Clean
Copyright

© MJH LifeSciences
Show Website

Treating Together